Cargando…
Non-canonical PD-1 signaling in cancer and its potential implications in clinic
Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally con...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888367/ https://www.ncbi.nlm.nih.gov/pubmed/33593825 http://dx.doi.org/10.1136/jitc-2020-001230 |
_version_ | 1783652147502514176 |
---|---|
author | Zha, Haoran Jiang, Ying Wang, Xi Shang, Jin Wang, Ning Yu, Lei Zhao, Wei Li, Zhihua An, Juan Zhang, Xiaochun Chen, Huoming Zhu, Bo Li, Zhaoxia |
author_facet | Zha, Haoran Jiang, Ying Wang, Xi Shang, Jin Wang, Ning Yu, Lei Zhao, Wei Li, Zhihua An, Juan Zhang, Xiaochun Chen, Huoming Zhu, Bo Li, Zhaoxia |
author_sort | Zha, Haoran |
collection | PubMed |
description | Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies. |
format | Online Article Text |
id | pubmed-7888367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-78883672021-03-03 Non-canonical PD-1 signaling in cancer and its potential implications in clinic Zha, Haoran Jiang, Ying Wang, Xi Shang, Jin Wang, Ning Yu, Lei Zhao, Wei Li, Zhihua An, Juan Zhang, Xiaochun Chen, Huoming Zhu, Bo Li, Zhaoxia J Immunother Cancer Review Programmed cell death 1 (PD-1)-based immunotherapy has revolutionized the treatment of various cancers. However, only a certain group of patients benefit from PD-1 blockade therapy and many patients succumb to hyperprogressive disease. Although, CD8 T cells and conventional T cells are generally considered to be the primary source of PD-1 in cancer, accumulating evidence suggests that other distinct cell types, including B cells, regulatory T cells, natural killer cells, dendritic cells, tumor-associated macrophages and cancer cells, also express PD-1. Hence, the response of patients with cancer to PD-1 blockade therapy is a cumulative effect of anti-PD-1 antibodies acting on a myriad of cell types. Although, the contribution of CD8 T cells to PD-1 blockade therapy has been well-established, recent studies also suggest the involvement of non-canonical PD-1 signaling in blockade therapy. This review discusses the role of non-canonical PD-1 signaling in distinct cell types and explores how the available knowledge can improve PD-1 blockade immunotherapy, particularly in identifying novel biomarkers and combination treatment strategies. BMJ Publishing Group 2021-02-16 /pmc/articles/PMC7888367/ /pubmed/33593825 http://dx.doi.org/10.1136/jitc-2020-001230 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Zha, Haoran Jiang, Ying Wang, Xi Shang, Jin Wang, Ning Yu, Lei Zhao, Wei Li, Zhihua An, Juan Zhang, Xiaochun Chen, Huoming Zhu, Bo Li, Zhaoxia Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title_full | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title_fullStr | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title_full_unstemmed | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title_short | Non-canonical PD-1 signaling in cancer and its potential implications in clinic |
title_sort | non-canonical pd-1 signaling in cancer and its potential implications in clinic |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888367/ https://www.ncbi.nlm.nih.gov/pubmed/33593825 http://dx.doi.org/10.1136/jitc-2020-001230 |
work_keys_str_mv | AT zhahaoran noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT jiangying noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT wangxi noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT shangjin noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT wangning noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT yulei noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT zhaowei noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT lizhihua noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT anjuan noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT zhangxiaochun noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT chenhuoming noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT zhubo noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic AT lizhaoxia noncanonicalpd1signalingincanceranditspotentialimplicationsinclinic |